Literature DB >> 27452519

Human EHMT2/G9a activates p53 through methylation-independent mechanism.

M Rada1, E Vasileva2, L Lezina1,2, D Marouco1, A V Antonov2,3, S Macip1, G Melino3, N A Barlev2.   

Abstract

p53 is a critical tumor suppressor in humans. It functions mostly as a transcriptional factor and its activity is regulated by numerous post-translational modifications. Among different covalent modifications found on p53 the most controversial one is lysine methylation. We found that human G9a (hG9a) unlike its mouse orthologue (mG9a) potently stimulated p53 transcriptional activity. Both ectopic and endogenous hG9a augmented p53-dependent transcription of pro-apoptotic genes, including Bax and Puma, resulting in enhanced apoptosis and reduced colony formation. Significantly, shRNA-mediated knockdown of hG9a attenuated p53-dependent activation of Puma. On the molecular level, hG9a interacted with histone acetyltransferase, p300/CBP, resulting in increased histone acetylation at the promoter of Puma. The bioinformatics data substantiated our findings showing that positive correlation between G9a and p53 expression is associated with better survival of lung cancer patients. Collectively, this study demonstrates that depending on the cellular and organismal context, orthologous proteins may exert both overlapping and opposing functions. Furthermore, this finding has important ramifications on the use of G9a inhibitors in combination with genotoxic drugs to treat p53-positive tumors.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27452519     DOI: 10.1038/onc.2016.258

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  54 in total

1.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis.

Authors:  E Oda; R Ohki; H Murasawa; J Nemoto; T Shibue; T Yamashita; T Tokino; T Taniguchi; N Tanaka
Journal:  Science       Date:  2000-05-12       Impact factor: 47.728

Review 2.  Is there a code embedded in proteins that is based on post-translational modifications?

Authors:  Robert J Sims; Danny Reinberg
Journal:  Nat Rev Mol Cell Biol       Date:  2008-09-11       Impact factor: 94.444

3.  Histone H1 variant-specific lysine methylation by G9a/KMT1C and Glp1/KMT1D.

Authors:  Thomas Weiss; Sonja Hergeth; Ulrike Zeissler; Annalisa Izzo; Philipp Tropberger; Barry M Zee; Miroslav Dundr; Benjamin A Garcia; Sylvain Daujat; Robert Schneider
Journal:  Epigenetics Chromatin       Date:  2010-03-24       Impact factor: 4.954

4.  G9a functions as a molecular scaffold for assembly of transcriptional coactivators on a subset of glucocorticoid receptor target genes.

Authors:  Danielle Bittencourt; Dai-Ying Wu; Kwang Won Jeong; Daniel S Gerke; Laurie Herviou; Irina Ianculescu; Rajas Chodankar; Kimberly D Siegmund; Michael R Stallcup
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-14       Impact factor: 11.205

5.  Modulation of p53 function by SET8-mediated methylation at lysine 382.

Authors:  Xiaobing Shi; Ioulia Kachirskaia; Hiroshi Yamaguchi; Lisandra E West; Hong Wen; Evelyn W Wang; Sucharita Dutta; Ettore Appella; Or Gozani
Journal:  Mol Cell       Date:  2007-08-17       Impact factor: 17.970

6.  Histone H3 lysine 9 methyltransferase G9a is a transcriptional coactivator for nuclear receptors.

Authors:  David Y Lee; Jeffrey P Northrop; Min-Hao Kuo; Michael R Stallcup
Journal:  J Biol Chem       Date:  2006-02-04       Impact factor: 5.157

7.  BioProfiling.de: analytical web portal for high-throughput cell biology.

Authors:  Alexey V Antonov
Journal:  Nucleic Acids Res       Date:  2011-05-23       Impact factor: 16.971

8.  Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294.

Authors:  Yanqi Chang; Xing Zhang; John R Horton; Anup K Upadhyay; Astrid Spannhoff; Jin Liu; James P Snyder; Mark T Bedford; Xiaodong Cheng
Journal:  Nat Struct Mol Biol       Date:  2009-02-15       Impact factor: 15.369

9.  DNA damage-induced ubiquitylation of proteasome controls its proteolytic activity.

Authors:  Tatiana N Moiseeva; Andrew Bottrill; Gerry Melino; Nickolai A Barlev
Journal:  Oncotarget       Date:  2013-09

10.  KMT Set7/9 affects genotoxic stress response via the Mdm2 axis.

Authors:  Larissa Lezina; Vasilisa Aksenova; Olga Fedorova; Daria Malikova; Oleg Shuvalov; Alexey V Antonov; Dmitri Tentler; Alexander V Garabadgiu; Gerry Melino; Nikolai A Barlev
Journal:  Oncotarget       Date:  2015-09-22
View more
  16 in total

Review 1.  A drive in SUVs: From development to disease.

Authors:  Vinay Kumar Rao; Ananya Pal; Reshma Taneja
Journal:  Epigenetics       Date:  2017-01-20       Impact factor: 4.528

2.  G9a coordinates with the RPA complex to promote DNA damage repair and cell survival.

Authors:  Qiaoyan Yang; Qian Zhu; Xiaopeng Lu; Yipeng Du; Linlin Cao; Changchun Shen; Tianyun Hou; Meiting Li; Zhiming Li; Chaohua Liu; Di Wu; Xingzhi Xu; Lina Wang; Haiying Wang; Ying Zhao; Yang Yang; Wei-Guo Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-11       Impact factor: 11.205

3.  The expanding role of the Ehmt2/G9a complex in neurodevelopment.

Authors:  Steven J Deimling; Jonathan B Olsen; Vincent Tropepe
Journal:  Neurogenesis (Austin)       Date:  2017-05-02

Review 4.  Potential Therapeutics Targeting Upstream Regulators and Interactors of EHMT1/2.

Authors:  Gareth Chin Khye Ang; Amogh Gupta; Uttam Surana; Shirlyn Xue Ling Yap; Reshma Taneja
Journal:  Cancers (Basel)       Date:  2022-06-09       Impact factor: 6.575

Review 5.  Opposing Roles of Wild-type and Mutant p53 in the Process of Epithelial to Mesenchymal Transition.

Authors:  Oleg Semenov; Alexandra Daks; Olga Fedorova; Oleg Shuvalov; Nickolai A Barlev
Journal:  Front Mol Biosci       Date:  2022-06-23

6.  BTK blocks the inhibitory effects of MDM2 on p53 activity.

Authors:  Miran Rada; Mohammad Althubiti; Akang E Ekpenyong-Akiba; Koon-Guan Lee; Kong Peng Lam; Olga Fedorova; Nickolai A Barlev; Salvador Macip
Journal:  Oncotarget       Date:  2017-11-20

7.  The novel indomethacin derivative CZ-212-3 exerts antitumor effects on castration-resistant prostate cancer by degrading androgen receptor and its variants.

Authors:  Hong Wang; Zhe Chang; Guo-di Cai; Ping Yang; Jiang-He Chen; Shan-Shu Yang; Yin-Feng Guo; Ming-Yu Wang; Xue-Hua Zheng; Jin-Ping Lei; Pei-Qing Liu; De-Peng Zhao; Jun-Jian Wang
Journal:  Acta Pharmacol Sin       Date:  2021-07-28       Impact factor: 6.150

8.  A novel class of inhibitors that target SRSF10 and promote p53-mediated cytotoxicity on human colorectal cancer cells.

Authors:  Muhammad Sohail; Lulzim Shkreta; Johanne Toutant; Safwat Rabea; Jean-Philippe Babeu; Caroline Huard; Jasmin Coulombe-Huntington; Aurélie Delannoy; Morgane Placet; Sameh Geha; Fernand-Pierre Gendron; François Boudreau; Mike Tyers; David S Grierson; Benoit Chabot
Journal:  NAR Cancer       Date:  2021-05-25

9.  Methyltransferase G9a promotes cervical cancer angiogenesis and decreases patient survival.

Authors:  Ruey-Jien Chen; Chia-Tung Shun; Men-Luh Yen; Chia-Hung Chou; Ming-Chieh Lin
Journal:  Oncotarget       Date:  2017-07-07

10.  YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells.

Authors:  Chun-Chia Cheng; Jungshan Chang; Stanley Ching-Cheng Huang; Huan-Chau Lin; Ai-Sheng Ho; Ken-Hong Lim; Chun-Chao Chang; Ling Huang; Yu-Cheng Chang; Yi-Fang Chang; Cheng-Wen Wu
Journal:  PLoS One       Date:  2017-08-07       Impact factor: 3.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.